Makair Tablet contains Levocetirizine and Montelukast, a combination used for the management of allergic conditions. Levocetirizine is a potent, selective antagonist of peripheral H1 histamine receptors, providing effective relief from symptoms such as sneezing, rhinorrhea, nasal itching, and urticaria by inhibiting the action of histamine released during allergic reactions. Montelukast is a leukotriene receptor antagonist that blocks leukotriene D4 at the cysteinyl leukotriene receptor, thereby reducing inflammation, bronchoconstriction, and mucus production associated with asthma and allergic rhinitis. The combined action of these two agents offers comprehensive control of allergic symptoms and improves respiratory function in patients with seasonal allergic rhinitis, perennial allergic rhinitis, and asthma. Makair Tablet is typically prescribed for adults and children above a certain age as determined by a healthcare professional. It is generally well-tolerated, with common side effects including headache, fatigue, and gastrointestinal disturbances. Patients with hepatic or renal impairment should use this medication cautiously under medical supervision. Makair Tablet should be taken as directed, usually once daily in the evening, to optimize therapeutic efficacy and improve patient compliance. It is important to consult a healthcare provider before initiating treatment to ensure suitability and monitor for potential drug interactions.